Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease

References

• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival Plateau. Br J Haematol. 2016;175(3):410–418. doi:10.1111/bjh.14241
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous Stem-Cell transplantation in Mantle-Cell lymphoma. N Engl J Med. 2017;377(13):1250–1260. doi:10.1056/NEJMoa1701769
   PubMed Web of Science ®Google Scholar
• Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard First-Line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022;140(Supplement 1):1–3. doi:10.1182/blood-2022-163018
   PubMedGoogle Scholar
• Lew TE, Minson A, Dickinson M, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10(2):e142–e154. doi:10.1016/S2352-3026(22)00355-6
   PubMed Web of Science ®Google Scholar
• Jain P, Dreyling M, Seymour JF, et al. High-Risk mantle cell lymphoma: definition, current challenges, and management. J Clin Oncol. 2020;38(36):4302–4316. doi:10.1200/JCO.20.02287
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910. doi:10.1182/blood-2017-04-779736
   PubMed Web of Science ®Google Scholar
• Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated Mantle-Cell lymphoma. N Engl J Med. 2022; Jun 30386(26):2482–2494. doi:10.1056/NEJMoa2201817
   PubMed Web of Science ®Google Scholar
• Halldórsdóttir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011;25(12):1904–1908. doi:10.1038/leu.2011.162
   PubMed Web of Science ®Google Scholar
• Obr A, Klener P, Furst T, et al. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol. 2020;191(5):e103–e106. doi:10.1111/bjh.17063
   PubMed Web of Science ®Google Scholar
• Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the european MCL network. Blood. 2018;131(4):417–420. doi:10.1182/blood-2017-07-797019
   PubMed Web of Science ®Google Scholar
• Rodrigues JM, Hassan M, Freiburghaus C, et al. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol. 2020;191(5):796–805. doi:10.1111/bjh.17023
   PubMedGoogle Scholar
• Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211–e214. doi:10.3324/haematol.2018.205229
   PubMed Web of Science ®Google Scholar
• Dreyling M, Goy A, Hess G, et al. Long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up. Hemasphere. 2022;6(5):e712. doi:10.1097/HS9.0000000000000712
   PubMed Web of Science ®Google Scholar
• Handunnetti SM, Anderson MA, Burbury K, et al. Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study. Blood. 2019;134(Supplement_1):756–756. doi:10.1182/blood-2019-126619
   Web of Science ®Google Scholar
• Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of Mantle-Cell lymphoma. N Engl J Med. 2018;378(13):1211–1223. doi:10.1056/NEJMoa1715519
   PubMed Web of Science ®Google Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71. doi:10.3324/haematol.2018.198812
   PubMed Web of Science ®Google Scholar
• Lew TE, Seymour JF. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. J Hematol Oncol. 2022;15(1):75. doi:10.1186/s13045-022-01295-3
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi:10.1056/NEJMoa1914347
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including High-Risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–567. doi:10.1200/JCO.21.02370
   PubMed Web of Science ®Google Scholar
• Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-Care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594–2606. doi:10.1200/JCO.22.01797
   PubMed Web of Science ®Google Scholar
• Minson A, Hamad N, Cheah CY, et al. Time-Limited ibrutinib and tisagenlecleucel is highly effective in the treatment of patients with relapsed or refractory mantle cell lymphoma, including those with TP53 mutated and Btki-Refractory disease: first report of the tarmac study. Blood. 2022;140(Supplement 1):181–183. doi:10.1182/blood-2022-160459
   Google Scholar
• Phillips T, Dickinson M, Morschhauser F, et al. Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL), most of whom had failed prior bruton’s tyrosine kinase inhibitor (BTKi) therapy. Blood. 2021;138(Supplement 1):130–130. doi:10.1182/blood-2021-148949
   Google Scholar
• Rule S, Cook G, Russell NH, et al. Allogeneic stem cell transplantation as part of front line therapy for mantle cell lymphoma. Br J Haematol. 2019;184(6):999–1005. doi:10.1111/bjh.15723
   PubMed Web of Science ®Google Scholar
• Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson cancer center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113(18):4144–4152. Apr 30doi:10.1182/blood-2008-10-184200
   PubMed Web of Science ®Google Scholar
• Munshi PN, Hamadani M, Kumar A, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021;56(12):2911–2921. doi:10.1038/s41409-021-01288-9
   PubMed Web of Science ®Google Scholar
• Lin RJ, Ho C, Hilden PD, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019;184(6):1006–1010.
   PubMed Web of Science ®Google Scholar
• Lew TE, Cliff ERS, Dickinson M, et al. T-cell replete ­allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone Marrow Transplant. 2021;56(11):2857–2859. doi:10.1038/s41409-021-01418-3
   PubMed Web of Science ®Google Scholar
• Grigg A, Bardy P, Byron K, et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant. 1999;23(2):107–110. doi:10.1038/sj.bmt.1701540
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Bento L, Novelli S, et al. Allogeneic stem cell transplantation in mantle cell lymphoma; insights into its potential role in the era of new immunotherapeutic and targeted therapies: the GETH/GELTAMO experience. Cancers (Basel). 2022;14(11):2673. doi:10.3390/cancers14112673
   PubMed Web of Science ®Google Scholar
• Michallet M, Dreger P, Sobh M, et al. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplant. 2020;55(5):884–890. doi:10.1038/s41409-019-0742-7
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory Mantle-Cell lymphoma with zanubrutinib, a selective inhibitor of bruton’s tyrosine kinase. Clin Cancer Res. 2020;26(16):4216–4224. doi:10.1158/1078-0432.CCR-19-3703
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148–3158. doi:10.1182/blood.2021014162
   PubMed Web of Science ®Google Scholar